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Abstract: A recent study demonstrated the lack of beta-amyloid (Aβ) plaque formation and accumulation of the
amyloid precursor protein (APP) in a triple transgenic mouse model of Alzheimer’s disease (3xTg-AD) following
overexpression of the anti-apoptotic protein, Bcl-2 (Rohn et al., J. Neurosci. 28: 3051-9, 2008). The supposition
from that study was the accumulation of APP resulted from a decrease in caspase-mediated processing of APP.
To determine a direct role for the caspase-cleavage of APP in 3xTg-AD mice, we designed a site-directed caspasecleavage antibody to APP and demonstrated it is a specific marker for caspase-cleaved APP. Application of this
antibody revealed neuronal staining in the hippocampus and subiculum of 3xTg-AD mice. These results were
confirmed utilizing a similar site-directed antibody to caspase-cleaved APP (APPneo). The caspase cleavage of
APP as well as the formation of extracellular Aβ plaques was prevented in 3xTg-AD animals overexpressing Bcl-2.
These results provide further support that caspases play a proximal role in promoting the pathology associated
with AD.
Key Words: Amyloid precursor protein, beta-amyloid, caspase; mouse model, neurofibrillary tangles, plaques; tau;
bcl-2; apoptosis

Introduction
In Alzheimer’s disease, Aβ deposition is
accompanied by the gradual replacement of
the neuronal cytoskeleton with insoluble NFTs.
NFTs are intracellular fibrillary inclusions
composed of aggregations of paired helical
filaments (PHFs), which are made up of
abnormally phosphorylated and truncated tau
[1]. According to the Aβ hypothesis, Aβ
precedes NFT formation, suggesting that Aβ
may be the earliest event that triggers
downstream events [2]. Several studies have
supported the hypothesis that Aβ formation
and NFT formation may be closely linked
through a common pathway of caspasemediated proteolysis [3-5]. Direct evidence
supporting a role for caspases in promoting

the pathology associated with AD come from
several transgenic mouse studies: Galvan et
al. demonstrated that deleting the C-terminal
caspase-cleavage consensus site within APP
reversed the pathology and behavioral deficits
associated with human APP transgenic mice
[6]. In a recent study by Spires-Jones et al.,
the authors used in vivo imaging in rTg4510
mice, a reversible mouse model of tauopathy,
to demonstrate the activation of caspases
within tangle-bearing neurons [7]. Finally, we
have developed a triple-transgenic mouse
model (3xTg-AD) that overexpress the antiapoptotic protein, Bcl-2, in all postmitotic
neurons of the CNS. Overexpression of Bcl-2
prevented caspase activation, the caspase
cleavage of tau and improved place
recognition memory in 3xTg-AD mice [8]. An
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additional finding of that study was the
accumulation of full-length APP and tau
following overexpression of Bcl-2 in 3xTg-AD
mice [8]. The interpretation of this finding was
the observed accumulation of APP and tau
resulted from an inhibition in caspasemediated proteolysis following overexpression
of Bcl-2. However, direct demonstration that
APP is cleaved by caspases and is prevented
following overexpression of Bcl-2 was not
investigated. The goal of the present study
was examine directly a role for caspasemediated cleavage of APP in 3xTg-AD mice
utilizing a novel site-directed caspase-cleavage
antibody to APP. Following application of this
antibody and a similar antibody developed by
Galvan et al. [6], we now demonstrate
caspase-cleavage of APP does occur in 3xTgAD mice and is prevented along with the
formation of extracellular deposits of Aβ
following overexpression of Bcl-2. These
results provide further support for a role of
caspases in the disease progression
associated with AD.
Methods and Materials
Animals
The generation and characterization of 3xTgAD mice that overexpress the anti-apoptotic
protein, Bcl-2, have been described previously
[8]. In brief, 3xTg-AD mice harbor three known
mutations, human APPSwe, human tauP301L and
PS1M146V known to give rise to the heritable
forms of AD [9]. These mice, termed 3xTg-AD
mice, progressively develop plaques and
tangles in a manner that closely recapitulates
the disease process in the human AD brain
[9]. To generate 3xTg-AD mice that
overexpress the anti-apoptotic protein, Bcl-2,
3xTg-AD mice were crossed with Tg mice that
overexpress the human Bcl-2 gene in all postmitotic neurons [10]. The progeny resulting
from such a cross have been termed 3xTgAD/Bcl-2 overexpressors (3xTg-AD/Bcl-2 OE).
Littermates that were negative for the human
Bcl-2 gene were used for comparison.
Tissue acquisition
Mice were anesthetized with pentobarbital,
perfused with saline, and the brains rapidly
removed.
Brains were divided into
hemispheres and one hemisphere was sunk in
4% phosphate-buffered paraformaldehyde,
while the other hemisphere was snap frozen at
49

–50°C in isopentane. Mouse brains were
mounted coronally and sectioned serially at 50
µm on a vibratome, and stored for
immunohistochemistry.
Generation of a caspase-cleavage, sitedirected antibody to the amyloid precursor
protein
Previous studies have demonstrated the
caspase-3 cleavage of the 120 kDa peptide of
APP results in two small fragments (23 and 25
kDa); both of these sites are within the first
220 amino acids while a third cleavage site at
aspartic residue 739, creates a larger
polypeptide (~85 kDa) [11]. A polyclonal
antibody, herein termed APP caspase-cleavage
product (ccp) was synthesized based upon a
putative caspase-3 cleavage site (VEVD739)
within APP [11]. A 7-mer peptide (HGVVEVD)
corresponding to the upstream neoepitope
fragment, that would be generated following
cleavage, was coupled to a cysteine group to
facilitate the conjugation of the adjuvant, KLH.
The resulting peptide ([KLH] - CHGVVEVD) was
injected into rabbits and the resulting sera was
used to affinity purify antibodies using a
sulfolink column coupled with the peptide
(CHGVVEVD). Synthesis of peptides, injections
of immunogens, and collection of serum was
completed
by
Bethyl
laboratories
(Montgomery, TX).
Antibody dilutions
Primary antibodies used in immunohistochemical analysis were diluted as follows:
APPccp, 1:100-150; mAB 1560 anti-A (clone
6e10, Chemicon, Temecula, CA), 1:400;
APPneo, 1:1000; and Tau C3 (Chemicon,
Temecula, CA), 1:100.
Cerebral ischemia produced by middle
cerebral artery occlusion, a model of apoptosis
Brain sections were generously provided to us
by Dr. Sheng T. Hou (Experimental
NeuroTherapeutics
Laboratory,
National
Research Council Institute for Biological
Sciences, National Research Council Canada,
Ottawa, Ontario, Canada). C57BL/6 mice (2023 g) were subjected to middle cerebral artery
occlusion (MCAO) as described previously [12].
Briefly, under anesthesia, mice were subjected
to MCAO using an intraluminal filament for 1
hr. After 1 hr of MCAO, the filament was
removed and blood flow was restored for 24 hr
Int J Physiol Pathophysiol Pharmacol 2009;1:48-56
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Fluoro Jade C labeling
To assess for neurodegeneration and
apoptosis, the fluorescent dye, Fluoro Jade C
(Millipore, catalog number AG325) was utilized
as previously described by Bian et al. [13].
Briefly, fixed brain sections were mounted and
pretreated for 5 min in a 80% alcohol solution
containing 1% sodium hydroxide, followed by a
70% alcohol and a distilled water wash for 2
min. Sections were then incubated for 10 min
in a 0.06% potassium permanganate solution
followed by rinsing in distilled water for 2 min.
Sections were then transferred into a
0.0001% solution of Fluoro Jade C containing
0.1% acetic acid for 10 min. Following 3
successive washes in distilled water for 1 min,
slides were dried, dehydrated and coverslipped with Depex.
Cell-free digestion of APP

Figure 1. Characterization of the APPccp antibody
in vitro. (A): ELISA results utilizing preimmune
(circles) or immunized (squares) sera indicated a
high titer of antibody following immunization of
rabbits with the peptide, [KLH]-CHGVVEVD. Results
are representative of three separate experiments
ran in triplicate, ±S.E.M. (B) Recombinant human
APP was incubated in the presence or absence of
caspase-3 for 2 hours at 37°C. Samples were
separated by SDS-PAGE and gels were stained with
coomassie blue (left panel) or transferred to
nitrocellulose and probed with affinity-purified
APPccp antibody (1:500). Incubation of full-length
APP with caspase-3 led to efficient processing and
formation of two prominent fragments (65 and 25
kDa, left panel). Western blot analysis indicated
that the APPccp antibody recognizes only the
caspase-cleaved fragment (~25 kDa) fragment and
does not detect full length APP (~100 kDa).

at which time animals were sacrificed. Mouse
brains were perfused with 10% formalin in
PBS, then post-fixed in 10% formalin for 4 hr
and cryo-protected overnight in phosphate
buffer containing 30% sucrose at 4°C.
Following fixation, brains were sectioned into
50 µm free-floating sections to be processed
by immunohistochemistry. Apoptotic areas
were identified by Hoechst staining as
described previously [12].
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To examine whether caspase-3 can cleave
APP, 1 µg of purified human recombinant APP
(Calbiochem) was incubated with active
human recombinant caspase-3 (Calbiochem)
in 2x reaction buffer containing 10 mM DTT for
two hours at 37°C.
Reactions were
terminated by the addition of 5x sample buffer
and stored at -20°C until analyzed.
ELISA
Antibody titers were determined with an
enzyme-linked immunoassay (ELISA). Samples
were run in triplicate on ELISA plates coated
with the peptide, CHGVVEVD, which was used
as the immunogen. The peptide CHGVVEVD
was bound in solid phase on high binding 96
well plates (Dynex Technologies). Serum was
diluted 1:500 and then serially diluted to a
final dilution of 1:64,000. Detection of the
antibody was obtained using an HRP
conjugated secondary antibody (1:5,000) and
TMB micro well peroxidase substrate (KPL
Protein Research Products).
Human Subjects
Autopsy brain tissue from the hippocampus
and entorhinal cortex of five neuropathologically confirmed AD cases and five
nondemented cases diagnosed as normal was
studied. Human brain tissues used in this
study were provided by the Institute for Brain
Aging and Dementia Tissue Repositories at the
University of California, Irvine.
Int J Physiol Pathophysiol Pharmacol 2009;1:48-56
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Immunohistochemistry and
immunofluorescence
Free-floating 50 µm-thick serial sections were
used
for
immunohistochemical
and
immunofluorescence studies conducted as
previously described by Mouser et al., [14].
Antigen visualization was determined using
ABC complex (ABC Elite immunoperoxidase kit,
Vector labs), followed by DAB substrate (brown
product) or with nickel chloride, which
generates a black product or NovaRed, which
generates an orange product (Vector Labs).
MCAO brain sections were labeled with APPccp
antibody (1:100) followed by streptavidin Alexa
Fluor 555 (red, Ex/Em = 555/565). To
visualize nuclei, sections were also incubated
in Hoechst.
Western blot analysis
Full-length APP, or APP digested with caspase3 were stored in 5x sample buffer at -20°C
until analyzed. Samples were boiled for 5
minutes, placed on ice then loaded onto 12%
SDS-PAGE gels. Gels were either stained with
coomassie blue to detect total protein content,
or slabs were transferred to nitrocellulose for
Western blot analysis. Western blot analysis
was performed utilizing the One-StepTM
Advanced Western rabbit kit according to
manufacturer’s
directions
(GenScript
Corporation, Piscataway, NJ). Samples were
analyzed for protein content using the BCA
assay (Pierce) to ensure equal protein loading.

affinity purification, we tested the specificity of
this antibody (herein termed the APP caspasecleavage product (ccp) antibody) utilizing a
cell-free system consisting of purified human
recombinant APP incubated with or without
caspase-3.
Following digestion of APP,
samples were separated by SDS-PAGE gel
electrophoresis and either stained with
coomassie blue (left panel, Figure 1B) or
transferred to nitrocellulose and probed with
the APPccp antibody (right panel, Figure 1B).
While no immunoreactivity was evident in nondigested samples, a prominent band was
visible at 25 kDa, corresponding to the 25 kDa
fragment generated following digestion of APP
with caspase-3 (Figure 1B, right panel). These
results indicate the APPccp antibody
recognizes only the caspase-cleaved fragment
(~25 kDa) and does not detect full length APP
(~100 kDa).
Experiments were performed to further
characterize the APPccp antibody in an in vivo
model system of ischemia, which has

Results
Characterization of a site-directed caspasecleavage antibody to APP
To examine whether APP is a target for
caspase cleavage in 3xTg-AD mice, we
synthesized a site-directed antibody according
to a putative caspase cleavage site (VEVD739)
located at the C-terminal end of APP. The
antibody was directed towards the upstream
neo-fragment that would be generated
following cleavage by caspase-3 at this site.
Cleavage of APP by caspase-3 at this
consensus site results in a predicted fragment
of 25 kDa [11]. An 8-mer peptide was
conjugated to KLH ([KLH]-CHGVVEVD) and
injected into rabbits. As shown in Figure 1A, a
strong antibody titer was obtained following
immunization of rabbits with this peptide as
compared to preimmune serum. Following
51

Figure 2. Detection of caspase-cleaved APP in an
animal model of apoptosis. Mice were subjected to
1 hr MCAO, followed by reperfusion for 24 hr. (A
and B): Brain sections incubated with Fluoro Jade
C revealed labeling of shrunken, damaged neurons
in the cortex of MCAO mice in ischemic infarct
areas (A), while no staining with Fluoro Jade C was
evident on the contralateral control side of the
brain (B). (C and D): Identical to Panels A and B
except sections were analyzed for caspase-cleaved
APP using the APPccp antibody. In this case,
APPccp staining (red) was evident in ischemic
infarct areas (C) and was largely absent on the
contralateral side of the brain (D). Nuclei were
identified following staining with Hoechst (Blue).
Scale bars represent 10µm.
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Figure 3. Characterization of APPccp antibody in the human AD brain by immunohistochemistry. Data are
representative staining from human postmortem hippocampal brain sections following application of the
APPccp antibody. (A): Representative age-matched control section following labeling with APPccp indicating a
general lack of staining. (B and C): Labeling of APPccp in a representative AD case was evident within
hippocampal neurons with apparent NFT morphology (arrow, B) and within plaque-rich regions (arrows, C).

previously been shown to activate apoptotic
pathways [12]. The advantage of this model is
that it creates an ischemic infarct confined to
one side of the brain while leaving the other
hemisphere undamaged, which thus can serve
as an internal control. As an initial approach,
we first determined whether we could detect
neurodegeneration in ischemic infarct regions
of MCAO mice.
To accomplish this, we
employed the use of a specific marker for
neurodegeneration, Fluoro Jade C. Fluoro
Jade C is a fluorescent dye that detects
neuronal degeneration in animal models and
displays a high degree of specificity and
sensitivity [13]. Application of Fluoro Jade C to
MCAO brain sections revealed widespread
neuronal labeling in ischemic infarct areas
(Figure 2A), while the contralateral side of the
brain showed no evidence of labeling (Figure
2B). These data suggest that activation of
apoptotic pathways and neurodegeneration
does indeed occur in MCAO mice. Sections
were further analyzed for caspase-cleaved APP
using APPccp and revealed the labeling of
neurons in ischemic infarct areas. For these
experiments, sections were also incubated
with the nuclear label, Hoechst (shown in blue,
Figure 2C) to indicate whether nuclei were
condensed or fragmented, a characteristic
morphological feature of apoptosis. In this
regard, we found co-localization of APPccp
within neurons that were clearly displaying
nuclear condensation and fragmentation
(Figure 2C). In contrast there was no labeling
of the APPccp antibody on the contralateral
side of the brain and the nuclei appeared
normal (Figure 2D). These data provide further
52

support that the APPccp antibody is a specific
probe for caspase-cleaved APP.
Following confirmation that the APPccp
antibody is specific for the C-terminal caspasecleavage fragment of APP, immunohistochemical analysis was performed using human
postmortem hippocampal sections from AD
and age-matched control brains. A previous
study has shown that APP is cleaved by
caspase-3
predominantly
within
the
cytoplasmic tail of APP, a cleavage event,
which also occurs in the human AD brain [11,
15]. In age-matched control sections, little
labeling was observed following application of
the APPccp antibody (Figure 3A). In contrast,
labeling of APPccp was evident within
hippocampal neurons, and within plaque-rich
regions in cases exhibiting pathology
consistent with AD (Figure 3B and C). Taken
together (Figs. 1-3), these findings validate the
APPccp as a specific probe to detect caspasecleaved APP.
Detection of caspase-cleaved APP in 3xTg-AD
and its prevention following overexpression of
Bcl-2
To test whether the caspase-cleavage of APP
occurs in 3xTg-AD mice, brain sections of 18
and 24 month-old mice were analyzed by
immunohistochemistry. Little labeling was
observed in age-matched nonTg control mice
(data not shown). Strong neuronal labeling
was evident primarily within the subiculum in
both 18 and 24 month-old 3xTg-AD mice
(Figure 4A and C). Interesting, the APPccp
Int J Physiol Pathophysiol Pharmacol 2009;1:48-56
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Figure 4. Evidence for the caspase-cleavage of
APP in 3xTg-AD mice, which is prevented following
overexpression of Bcl-2. Immuno-histochemical
analysis following application of APPccp antibody
in hippocampal sections from 18 month-old 3xTgAD mice (A) or 24 month-old 3xTg-AD mice (C)
revealed neuronal staining within the subiculum.
In contrast, in age-matched 3xTg-AD mice
overexpressing Bcl-2 there was no evidence for
APPccp staining (B and D).
Data are
representative staining of a total of n = 3 mice
from each age group. All scale bars represent 10
µm.

Figure 5. Confirmation of the caspase-cleavage of
APP and its prevention following overexpression of
Bcl-2 utilizing APPneo. Application of APPneo, an
identical site-directed caspase-cleavage antibody
to APPccp developed by Galvan et al., [6],
indicated labeling in 3xTg-AD mice that was
prevented following overexpression of Bcl-2. (A
and B): Representative hippocampal staining in
CA3 region of a 18 month-old 3xTg-AD mice with
APPneo indicated strong labeling within neuronal
cell bodies and dystrophic neurites (A) that was
absent in 3xTg-AD/Bcl-2 OE mice (B). (C and D):
Similar results were observed in the cortex of 24
month-old 3xTg-AD mice (C) and 3xTg-AD/Bcl-2 OE
mice (D). All scale bars represent 10 µm.

antibody did not immuno-detect A plaques,
suggesting that the C-terminal cleavage
fragment of APP is not extracellularly
deposited. In contrast to 3xTg-AD mice, there
was no staining following application of the
APPccp
antibody
in
3xTg-AD
mice
overexpressing the antiapoptotic protein, Bcl-2
(Figure 4B and D). To confirm these findings,
we employed the use of a similar site-directed
caspase-cleavage antibody to APP developed
by Galvan et al. [6, 16]. This antibody, termed
APPneo, selectively recognizes the neo-Cterminus fragment of APP generated by
caspase-mediated cleavage of APP [16].
Application of APPneo in 3xTg-AD mice
revealed labeling within neuronal cell bodies
and dystrophic neurites in hippocampal and
cortical regions (Figure 5A and C), which was
absent in 3xTg-AD mice overexpressing Bcl-2
(Figure 5B and D).

tau [8].
To extend these findings, we
performed double-label immunohistochemical
experiments using the APPccp antibody
together with anti-Aβ 1560 (clone 6E10), an
antibody known to react with both the A
peptide as well as with full-length APP [17].
Strong staining of plaques with little neuronal
staining was observed following application of
the Aβ 1560 antibody in 3xTg-AD mice (brown
labeling, Figure 6A). Evidence for caspasecleaved APP was evident under the same
conditions following application of APPccp
(gray labeling, Figure 6A). In contrast, while
there was strong intracellular labeling with Aβ
1560, there was little evidence for caspasecleaved APP in 3xTg-AD mice overexpressing
Bcl-2 (Figure 6B). These results suggest that
overexpression of Bcl-2 prevents the caspasecleavage of APP as well as the extracellular
deposition of Aβ in 3xTg-AD mice.

In a previous study, overexpression of Bcl-2 in
3xTg-AD mice prevented the caspase cleavage
of tau, the formation of extracellular plaques,
and led to an accumulation of both APP and

Experiments were also performed to test
whether APPccp co-localized with an antibody
to caspase-cleaved tau (TauC3) developed by
Gamblin et al [4]. Double-label immunohisto-
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Figure 6. Prevention of extracellular plaque
formation and the caspase cleavage of APP and tau
in 3xTg-AD mice overexpressing Bcl-2. (A and B):
Double-label immunohistochemical analysis in 24
month-old 3xTg-AD mice utilizing mAB anti-A 1560
(red label) together with APPccp (blue) indicated a
lack of extracellular plaque deposition and APPccp
labeling in 3xTg-AD/Bcl- OE mice (B) compared to
3xTg-AD mice (A). (C and D): Double-labeling
immunohistochemical analysis with APPccp (blue)
and Tau C3 (red) shows co-localization of the two
antibodies within the subiculum of 24 month-old
3xTg-AD mice (C). In 3x-Tg-AD/Bcl-2 OE mice, a
reduction in the labeling of both antibodies was
observed (D). Data are representative staining from
n = 3 animals. All scale bars represent 10 µm.

chemical analysis with APPccp and TauC3
demonstrated co-localization of the two
antibodies within the subiculum of 24 monthold 3xTg-AD mice (Figure 6C). In 3xTg-AD/Bcl-2
OE mice, a reduction in the labeling of both
antibodies was observed indicating overexpression of Bcl-2 prevents caspase
activation and subsequent cleavage of target
proteins in 3xTg-AD mice (Figure 6D).
Discussion
The amyloid precursor protein (APP) is a
substrate for caspase-3 mediated cleavage,
which may contribute to Aβ formation, synaptic
loss, and the behavioral changes associated
with AD [6, 11, 18, 19]. The cleavage of APP
into Aβ represents an early stage in AD, and
previous research in this regard has focused
on secretase involvement (α, β and γ) [20].
Whether or not other proteases contribute to
the processing of APP is unknown, however,
studies have suggested that caspasemediated cleavage of APP may contribute to
54

Aβ formation and lead to the generation of a
cytotoxic C-terminal peptide termed C31 [2123].
We recently demonstrated an
accumulation of intracellular APP and a lack of
extracellular plaque formation in 3xTg-AD mice
following the overexpression of Bcl-2 [8]. Bcl-2
constitutes a critical control point in apoptosis
residing immediately upstream of irreversible
cellular damage, where it prevents the release
of apoptogenic factors from the mitochondria
[24]. One interpretation of these results
showing an accumulation of APP in 3xTgAD/Bcl-2 OE mice is that caspases play a role
in the turnover of this protein. Blocking
caspase activation by overexpressing Bcl-2
prevents cleavage and turnover of APP
allowing it to accumulate intracellularly within
neurons. However, direct evidence for the
caspase-cleavage of APP and its prevention
following overexpression of Bcl-2 was not
demonstrated [8]. The goal of the present
study was to examine this question directly by
utilizing a site-directed antibody to caspasecleaved APP based on a previous study by
Gervais et al. [11].
Following the experimental procedures setforth in this study, we synthesized an antibody
to the predicted upstream fragment that would
be generated following cleavage of full length
APP by caspase-3 at this site. To test the
specificity of our antibody we utilized a cellfree system consisting of purified human
recombinant APP incubated with and without
recombinant caspase-3. Western blot analysis
indicated that the APPccp antibody recognizes
only the caspase-cleaved fragment (~25 kDa)
but does not detect full length APP (~100
kDa), indicating that the antibody shows a high
degree of specificity for the cleaved fragment.
Following further verification of APPccp as a
specific marker for caspase-cleaved APP in
situ, we examined whether the antibody could
detect cleaved APP in 3xTg-mice and whether
this cleavage could be prevented following
overexpression of the anti-apoptotic protein,
Bcl-2. Utilizing this antibody as well as a
similar antibody, APPneo, develop by Galvan et
al. [16], we now provide evidence for the
caspase-cleavage of APP in 3xTg-AD mice that
is prevented following overexpression of Bcl-2.
These results confirm and extend our previous
findings and suggest that the caspasecleavage of APP is a proximal event that may
regulate the normal turnover of this protein
and contribute to extracellular deposition of
Aβ. The contribution to the formation of Aβ by
Int J Physiol Pathophysiol Pharmacol 2009;1:48-56
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caspases is predicted to occur by two different
mechanisms. One, is a through a direct
interaction of caspase-3 with the C-terminal
region of APP, leading to proteolytic processing
of APP [11]. Gervais et al., demonstrated that
cleavage of APP by caspase-3 enhanced Aβ
production five-fold [11].
Alternatively,
caspases may contribute to the formation of
Aβ, indirectly through cleavage of the beta-site
APP cleaving enzyme (BACE) trafficking
protein, GGA3. In a study by Tesco and
colleagues, caspase activation led to the
cleavage and stabilization of the BACE
trafficking molecule, GGA3. GGA3 plays a role
in sorting BACE to lysosomes allowing for
turnover of the enzyme. Consequently, after
caspase-3 activation and cleavage of GGA3,
there is increased availability of BACE leading
to enhanced production of Aβ [25]. Taken
together, our findings along with previous
studies, suggest that caspase activation may
be an early and important event associated
with the pathological mechanisms underlying
AD.
Therefore, therapeutics aimed at
inhibiting members of the caspase family may
provide a means of treating AD.
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